Skip to content
DataLookout
Menu

ROOT-ADNCT07923812

Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety of Disease-Modifying Therapy
Timeframe: From treatment initiation through up to 30 months of follow-up
Clinical Effectiveness of Disease-Modifying Therapy
Timeframe: Baseline and follow-up assessments up to 30 months

Secondary (9)

Change from baseline in Mini-Mental State Examination total score
Change from baseline in Montreal Cognitive Assessment total score
Change From Baseline in Amyloid Positron Emission Tomography (PET) Burden Measured in Centiloids
Duration of Disease-Modifying Therapy
Permanent Discontinuation of Disease-Modifying Therapy
Show 4 moreShow less
Change from baseline in the 20-Item Activities of Daily Living Scale Score
Change from baseline in Hamilton Anxiety Rating Scale total score
Change from baseline in the 17-Item Hamilton Depression Rating ScaleTotal Score
Change from baseline in the 12-Item Neuropsychiatric Inventory Total Score

Arms and interventions

Disease-Modifying Therapy Group

The disease-modifying therapy group includes patients with MCI-AD or AD dementia who received disease-modifying therapy during routine clinical practice. Patients were diagnosed based on clinical criteria and available biomarker evidence according to real-world clinical practice. Baseline characteristics, treatment information, clinical outcomes, and safety data will be retrospectively collected and analyzed.

Non-Disease-Modifying Therapy Group

The non-disease-modifying therapy group includes patients with MCI-AD or AD dementia who did not receive disease-modifying therapy. Patients may have received conventional symptomatic treatments or other non-disease-modifying treatments according to routine clinical practice. Clinical characteristics, treatment information, clinical outcomes, and safety data will be retrospectively collected and analyzed.

Drugs: Disease-Modifying Therapy

Sites

1 site in 1 country

  • Huashan Hospital, Fudan University, No. 12 Wulumuqi Middle Road, Jing'an District, ShanghaiShanghai, Jingan, China